intranasal

Nine Uttarakhand river stretches most polluted, says study-

India’s first intranasal Covid vaccine gets regulator’s nod-

admin

By Express News Service NEW DELHI:  The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech’s intranasal Covid ...

5,910 new COVID cases in India, active infections in country decline to 53,974-

India’s first intranasal vaccine for Covid gets DCGI approval-

admin

By PTI NEW DELHI: The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech’s intranasal Covid vaccine for ...

Bharat Biotech completes trials for India’s first intranasal Covid vaccine, says it's safe, immunoge-

Bharat Biotech completes trials for India’s first intranasal Covid vaccine, says it’s safe, immunoge-

admin

By Express News Service HYDERABAD: City-based Bharat Biotech on Monday announced it had completed clinical development for phase III trials ...

AIIMS Delhi to start booster dose trial of intranasal Covid vaccine from Friday-

AIIMS Delhi to start booster dose trial of intranasal Covid vaccine from Friday-

admin

By PTI NEW DELHI: The AIIMS will start the booster dose trial of Bharat Biotech’s intranasal COVID-19 vaccine from Friday. ...

Emergency use authorization request filed with FDA for paediatric use of Bharat Biotech's Covaxin-

DCGI allows Bharat Biotech to conduct phase-III trials for COVID’s intranasal booster dose-

admin

By PTI NEW DELHI/ HYDERABAD: India’s drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for ...

CDSCO approves shelf life of COVID-19 vaccines as 12.5 crore Indians are due for second dose-

Bharat Biotech seeks nod for phase-three trials of intranasal COVID vaccine as booster dose-

admin

By PTI HYDERABAD: Bharat Biotech has sought the Drug Controller General of India’s approval to conduct phase-3 trials of its ...

Intranasal Covid vaccine trials to likely end soon-

Intranasal Covid vaccine trials to likely end soon-

admin

By Express News Service NEW DELHI: After receiving go-ahead for Covaxin for the two-years plus population by the drug regulator’s ...